Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Ryan Gilbreth"'
Autor:
Kevin Schifferli, Gordon Moody, Karma Dacosta, Nina Chu, Ryan Gilbreth, Lori Clarke, Christina Gesse, Letizia Giardino, Cui Chen, Erin Sult, Noel Monks, Ravinder Tammali, Jon Chesebrough, Jessica Tong, Xiao-Tao Yao, Kapil Vashisht
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/4c51e28240674a9e93fe3715949db0c1
Autor:
Dewald van Dyk, Peter Zanvit, Christine Fazenbaker, Kelly McGlinchey, Weichuan Luo, Jessica Pezold, John Meekin, Chien-ying Chang, Benjamin Clark, Philip L. Martin, Clare Hoover, Eric Tu, Ryan Gilbreth, Mark Cobbold, Gordon Moody, Emily E. Bosco
Publikováno v:
Cancer Research. 83:LB085-LB085
Prostate cancer is traditionally considered an immunologically “cold” tumor type rendering patients insensitive to immunotherapy. Targeting surface antigens on tumors through cellular therapy can induce a potent anti tumor immune response to “h
Autor:
Qi Zhang, Qihan Fu, Wanyue Cao, Xingyuan Xu, Ao Xia, Jiaqi Huang, Andy Zou, Judy Zhu, Fei Wang, Yi Hong, Hui Wan, Yihong Yao, Nina Chu, Ryan Gilbreth, Maria Letizia Giardino Torchia, John Stone, Attilio Bondanza, Benny Farsaci, Gordon Moody, Mark Cobbold, Tingbo Liang
Publikováno v:
Cancer Research. 83:CT097-CT097
Introduction: Chimeric antigen receptor (CAR) T cells can mediate deep and durable responses in hematologic malignancies, however, achieving success in solid tumors has been so far limited largely by lack of suitable solid tumor-associated antigens a
Autor:
Mark A Sellmyer, Iris K Lee, Kyle Kuszpit, Jyoti Roy, Alex Alfaro, Virginie Ory, Lily Cheng, Daniel Sutton, Emily Bosco, Christine Fazenbaker, Shabazz Novarra, Ryan Gilbreth, Nick Tschernia, Deborah Berry, Xiaoru Chen, Yuling Wu, Ryan Wong
Publikováno v:
Cancer Immunology Research. 10:A37-A37
Genetically engineered medicines such as chimeric antigen receptor (CAR) T cells have great potential to be the next pillar of medical therapy beyond chemo- and traditional biologic therapies. To develop genetic medicines, new methods to understand t
Autor:
Maria Letizia Giardino Torchia, Ryan Gilbreth, Ashley Merlino, Erin Sult, Noel Monks, Jon Chesebrough, Ravinder Tammali, Nina Chu, Jessica Tong, John Meekin, Kevin Schifferli, Kapil Vashisht, Karma DaCosta, Lori Clarke, Christina Gesse, Xiao-Tao Yao, Courtney Bridges, Gordon Moody
Publikováno v:
Cytotherapy. 24(7)
Chimeric antigen receptor (CAR) T cell therapy has yielded impressive clinical results in hematological malignancies and is a promising approach for solid tumor treatment. However, toxicity, including cytokine-release syndrome (CRS) and neurotoxicity
Autor:
Nina J. Chu, Michael G. Overstreet, Ryan Gilbreth, Lori Clarke, Christina Gesse, Eric Tu, Gordon Moody, Maria Letizia Giardino Torchia
Publikováno v:
Cancer Research. 82:2837-2837
Background: Hepatocellular carcinoma (HCC) is the most common type of liver cancer and the third leading cause of cancer-related death worldwide. Immune checkpoint inhibitors have been recently approved in the first-line setting, however only 20-30%
Autor:
Lori A. Clarke, Michael G. Overstreet, Eric Tu, Christina Gesse, Nina Chu, Letizia Giardino, Gordon Moody, Ryan Gilbreth
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Chimeric antigen receptors (CARs) are engineered synthetic receptors that reprogram T cell specificity and function against a given antigen. Autologous CAR-T cell therapy has demonstrated potent efficacy against various hematological malig
Autor:
Nina Chu, Kevin Schifferli, Gordon Moody, Christina Gesse, Jon Chesebrough, Noel R. Monks, Letizia Giardino, Lori A. Clarke, Xiao-Tao Yao, Erin Sult, Kapil Vashisht, Karma Dacosta, Cui Chen, Jessica Tong, Ravinder Tammali, Ryan Gilbreth
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Chimeric antigen receptor (CAR)-T therapy has yielded impressive clinical results in hematological malignancies and it is a promising approach for solid tumor treatment. However, toxicity, including on-target off-tumor antigen binding, is
Publikováno v:
Cancer Research. 80:5178-5178
CD40 stimulation on antigen-presenting cells (APCs) promotes activation of CD8(+) cytotoxic T cells and several CD40 agonistic antibodies have shown promising anti-tumor activities in initial clinical trials. However, agonistic CD40 stimulation also
Autor:
Richard Kuras, Derrick R.J. Kolling, Antony R. Crofts, Ryan Gilbreth, Sangmoon Lhee, Sergei A. Dikanov, J. Todd Holland, Mariana Guergova Kuras, Doreen Victoria
Publikováno v:
Biochimica et Biophysica Acta (BBA) - Bioenergetics. 1777:1001-1019
Recent progress in understanding the Q-cycle mechanism of the bc(1) complex is reviewed. The data strongly support a mechanism in which the Q(o)-site operates through a reaction in which the first electron transfer from ubiquinol to the oxidized iron